Comparing Two Types of Diets on Psychological and Gastrointestinal Symptoms
5. mai 2020 oppdatert av: Johns Hopkins University
A Randomized Trial Comparing Two Types of Diets on Psychological and Gastrointestinal Symptoms
This pilot study proposes to gain a better understanding of the health benefits of the popular "paleo-diet" in patients with irritable bowel syndrome (IBS) and explore underlying mechanisms of benefit.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
In the proposed study, the primary hypothesis is that, compared with a customary diet, consumption of a paleo-diet will improve psychological and gastrointestinal symptoms in patients with irritable bowel syndrome.
Investigators also hypothesize consumption of the Paleolithic diet will result in decreased intestinal permeability, decreased inflammatory markers, and changes in the gut microbiome and microbiologic profiles.
Studietype
Intervensjonell
Registrering (Faktiske)
40
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Johns Hopkins University
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patients with mild to moderate Irritable Bowel Syndrome (IBS) and mild to moderate anxiety or depression
- Other causes of bowel symptoms excluded to the satisfaction of the Study Team
- Age at least 18 years at initial screening visit
- Patients who are able to sign and understand the study's informed consent form
- Patients able to complete all screening evaluations and procedures
Exclusion Criteria:
- Patients in inpatient hospital care
- Severe or refractory bowel or psychological symptoms
- Current consumption of a Paleolithic diet
- Known Celiac disease
- Uncontrolled thyroid disease as indicated by an abnormal thyroid stimulating hormone (TSH) level
- Uncontrolled diabetes as indicated by a HbA1c equal to 6.5 or greater
- Patients unable to speak English
- Inability to obtain informed consent
- Pregnant or nursing women
- Any condition, which in the opinion of the investigator, would interfere with study requirements
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Paleolithic Diet
|
Paleolithic diet
|
|
Aktiv komparator: General Healthful Diet
|
General Healthful Diet
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Vitality
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Vitality as measured on the vitality subscale of the short form health survey (SF36).
This instrument assesses vitality (energy level and fatigue) and is a subscale of SF36, a general health survey designed for use in clinical practice and research, health policy evaluation and general population surveys.
The Vitality Subscale score is determined by responses to 4 items: Did you feel full of life?
Did you have a lot of energy?
Did you feel worn out?
Did you feel tired?
The lower the score the more disability.
The higher the score the less disability.
|
The change between baseline and 4 weeks (post-intervention).
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Anxiety
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Anxiety as measured by the Generalized Anxiety Disorder 7-item (GAD-7) questionnaire. GAD-7 Questionnaire: This is a 7 item inventory rated on a 4 point Likert-type scale. Its purpose is to allow for brief and accurate detection of anxiety as well as for longitudinal anxiety symptom evaluation. Lower scores indicate less severe symptoms and higher scores equal more severe symptoms. |
The change between baseline and 4 weeks (post-intervention).
|
|
Depression
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Depression as measured by the Patient Health Questionnaire-9' (PHQ-9) questionnaire. PHQ-9: This is a 9 item inventory rated on a 4 point Likert-type scale. Its purpose is to allow for brief and accurate diagnosis of depression as well as for longitudinal depression symptom evaluation. Lower scores indicate less severe symptoms and higher scores equal more severe symptoms. |
The change between baseline and 4 weeks (post-intervention).
|
|
Activity level
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Activity level/amount of exercise as measured by the Godin Leisure-Time Exercise Questionnaire.
The Godin Leisure-Time Exercise Questionnaire is a simple questionnaire to measure a person's leisure time exercise.
It is designed to be reliable valid and easy to complete quickly without a need for detailed review.
Lower scores indicate less activity and higher scores equal more activity.
|
The change between baseline and 4 weeks (post-intervention).
|
|
Gastrointestinal symptoms
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Gastrointestinal symptoms as measured by the NIH-Promis Gastrointestinal Symptom Scale a. NIH-Promis Gastrointestinal Symptom Scales for 8 domains: Gastroesophageal reflux (13 items), disrupted swallowing (7 items), diarrhea (5 items), bowel incontinence/soilage (4 items), nausea and vomiting (4 items), constipation (9 items), belly pain (6 items), and gas/bloat/flatulence (12 items). Lower scores indicate less severe symptoms and higher scores equal more severe symptoms. |
The change between baseline and 4 weeks (post-intervention).
|
|
Visceral sensitivity
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Visceral sensitivity as measured by the Visceral Sensitivity Index.
Visceral Sensitivity Index assesses gastrointestinal-specific anxiety, the cognitive, affective, and behavioral response to fear of gastrointestinal sensations, symptoms, and the context in which these visceral sensations and symptoms occur.
Lower scores indicate less severe symptoms and higher scores equal more severe symptoms.
|
The change between baseline and 4 weeks (post-intervention).
|
|
Overall health status (Short Health Scale)
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Overall health status as measured by the Short Health Scale questionnaires.
The "Short Health Scale" is a 4-item questionnaire covering aspects of subjective health.
Lower scores indicate less severe symptoms and higher scores equal more severe symptoms.
|
The change between baseline and 4 weeks (post-intervention).
|
|
Overall health status (EQ-5D)
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Overall health status (global health outcomes measure) as measured by the EuroQol 5 Dimension (EQ-5D) The EQ-5D descriptive system consists of five dimensions: Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression.
Scores range from 5-25, with higher scores indicating more severe symptoms/decreased quality of life.descriptive
system consists of five dimensions: Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression.
Lower scores indicate less severe symptoms and higher scores equal more severe symptoms.
|
The change between baseline and 4 weeks (post-intervention).
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Intestinal permeability
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Change in intestinal permeability as measured by plasma zonulin levels
|
The change between baseline and 4 weeks (post-intervention).
|
|
Change in inflammatory markers
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Change in inflammatory markers as measured by serum C-reactive protein levels
|
The change between baseline and 4 weeks (post-intervention).
|
|
Change in stool metabolomics
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Change in stool metabolomics as measured by stool metabolite testing.
|
The change between baseline and 4 weeks (post-intervention).
|
|
Change in stool microbiome profile
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Change in stool microbiota profile as measured by 16S DNA sequencing of stool samples.
|
The change between baseline and 4 weeks (post-intervention).
|
|
Biobank specimen collection of urine.
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Biobank specimen collection of stool, blood, urine, and saliva to be studied in future studies
|
The change between baseline and 4 weeks (post-intervention).
|
|
Biobank specimen collection of stool.
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Biobank specimen collection of stool, blood, urine, and saliva to be studied in future studies
|
The change between baseline and 4 weeks (post-intervention).
|
|
Biobank specimen collection of saliva.
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Biobank specimen collection of stool, blood, urine, and saliva to be studied in future studies
|
The change between baseline and 4 weeks (post-intervention).
|
|
Biobank specimen collection of blood.
Tidsramme: The change between baseline and 4 weeks (post-intervention).
|
Biobank specimen collection of stool, blood, urine, and saliva to be studied in future studies
|
The change between baseline and 4 weeks (post-intervention).
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
24. april 2018
Primær fullføring (Faktiske)
1. april 2020
Studiet fullført (Faktiske)
1. april 2020
Datoer for studieregistrering
Først innsendt
18. januar 2017
Først innsendt som oppfylte QC-kriteriene
25. januar 2017
Først lagt ut (Anslag)
30. januar 2017
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
7. mai 2020
Siste oppdatering sendt inn som oppfylte QC-kriteriene
5. mai 2020
Sist bekreftet
1. mai 2020
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB00082222
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .